BioWorld

Aug. 24, 2006

View Archived Issues

Ablynx €40M Round Notable Among European Financings

In one of the largest European private placements conducted this year, Ablynx NV raised €40 million (US$51.2 million) in a Series C round to drive more of its programs into preclinical and clinical development. (BioWorld Today) Read More

Theravance's Phase III Data: Non-Inferior To Vancomycin

Read More

Debate Over Whether New Stem Cell Science Will Change Policy

Read More

Kemia Adds $31M In Series C, Reports Positive Phase I Data

Read More

Theratechnologies SPA Aligns Second TH9507 Pivotal Study

Read More

Other News To Note

Read More

Clinic Roundup

Read More

U.S. Patent Disclosures

Read More